| Name | Title | Contact Details |
|---|---|---|
Dan O'Neill |
Vice President of Information Technology | Profile |
Jeff Hrkach |
Senior Vice President of Technology Development | Profile |
Brain diseases collectively represent one of the greatest challenges of our generation, affecting upwards of 1.5 billion people. However, treatments for many of the most prevalent brain disorders have been dominated by a single class of drugs, such as serotonin targeting antidepressants for MDD, leaving patients with a high degree of unmet medical need given the lack of diverse treatment options and mechanisms of action. We are taking a fundamentally different approach to the way treatments for brain diseases are developed. Our pipeline is comprised of programs pursuing therapeutically relevant targets implicated in Central Nervous System (CNS) diseases, each targeting a novel mechanism of action with best-in-class pharmacology. Our work is supported by our Precision Toolbox, which integrates a suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora is relentless in its commitment to discovering, developing and commercializing novel therapies for the 1.5 billion people living with brain diseases.
Tasso is changing the way that care is delivered with simple, virtually painless, clinical-grade diagnostic testing that can be done from home.
Allied BioScience is a disruptive biotechnology company specializing in continuously active antimicrobial coatings providing 90 days of surface protection. Working across various industries and commercial settings, its customers include health systems, sports facilities, and other commercial partners. The company is dedicated to saving life through revolutionary science and focuses on developing innovative solutions to create cleaner human environments through long-lasting, always-on antimicrobial coatings.
Have your medicine tested at MCR Labs, an ISO-17025 accredited cannabis testing laboratory. We test cannabis products for harmful contaminants and provide cannabinoid profiling. A test requires 0.25 to 0.5 grams flower, 0.1 to 0.2 grams concentrate...
Cerecor is building a global biopharmaceutical enterprise with a near-term pipeline of six clinical programs. All of our pipeline products have unique and novel mechanisms of action with the potential to be first-in-class compounds.